BioInvent International AB (publ)
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more
Market Cap & Net Worth: BioInvent International AB (publ) (BOVNF)
BioInvent International AB (publ) (PINK:BOVNF) has a market capitalization of $309.28 Million ($309.28 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #16606 globally and #6375 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioInvent International AB (publ)'s stock price $4.70 by its total outstanding shares 65804362 (65.80 Million).
BioInvent International AB (publ) Market Cap History: 2015 to 2025
BioInvent International AB (publ)'s market capitalization history from 2015 to 2025. Data shows change from $494.06 Million to $309.28 Million (-4.83% CAGR).
BioInvent International AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioInvent International AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.92x
BioInvent International AB (publ)'s market cap is 6.92 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $494.06 Million | $15.93 Million | -$90.68 Million | 31.02x | N/A |
| 2016 | $325.92 Million | $71.28 Million | -$62.59 Million | 4.57x | N/A |
| 2017 | $371.39 Million | $45.01 Million | -$100.53 Million | 8.25x | N/A |
| 2018 | $371.39 Million | $38.55 Million | -$123.16 Million | 9.63x | N/A |
| 2019 | $230.32 Million | $93.74 Million | -$139.12 Million | 2.46x | N/A |
| 2020 | $329.02 Million | $147.37 Million | -$76.67 Million | 2.23x | N/A |
| 2021 | $436.28 Million | $19.38 Million | -$278.96 Million | 22.51x | N/A |
| 2022 | $309.28 Million | $326.13 Million | -$34.09 Million | 0.95x | N/A |
| 2023 | $309.28 Million | $71.46 Million | -$330.30 Million | 4.33x | N/A |
| 2024 | $309.28 Million | $44.69 Million | -$429.38 Million | 6.92x | N/A |
Competitor Companies of BOVNF by Market Capitalization
Companies near BioInvent International AB (publ) in the global market cap rankings as of March 19, 2026.
Key companies related to BioInvent International AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BioInvent International AB (publ) Historical Marketcap From 2015 to 2025
Between 2015 and today, BioInvent International AB (publ)'s market cap moved from $494.06 Million to $ 309.28 Million, with a yearly change of -4.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $309.28 Million | 0.00% |
| 2024 | $309.28 Million | 0.00% |
| 2023 | $309.28 Million | 0.00% |
| 2022 | $309.28 Million | -29.11% |
| 2021 | $436.28 Million | +32.60% |
| 2020 | $329.02 Million | +42.86% |
| 2019 | $230.32 Million | -37.99% |
| 2018 | $371.39 Million | 0.00% |
| 2017 | $371.39 Million | +13.95% |
| 2016 | $325.92 Million | -34.03% |
| 2015 | $494.06 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of BioInvent International AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $309.28 Million USD |
| MoneyControl | $309.28 Million USD |
| MarketWatch | $309.28 Million USD |
| marketcap.company | $309.28 Million USD |
| Reuters | $309.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.